Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients

American Journal of Kidney Diseases

Volumn 40, Issue 4, 2002, Pages 802-809

  Ueda, Misako ^a,b,c   Inaba, Masaaki ^a,b,c   Okuno, Senji ^a,b,c   Nagasue, Kyoko ^a,b,c   Kitatani, Kayoko ^a,b,c   Ishimura, Eiji ^a,b,c   Shimizu, Motokazu ^a,b,c   Miki, Takami ^a,b,c   Kim, Masao ^a,b,c   Nishizawa, Yoshiki ^a,b,c  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shirasagi Hospital   (Japan)

^c Nozaki Clinic   (Japan)

Author keywords

Bone formation marker; Bone loss; Chronic renal failure (CRF); Collagen I amino terminal propeptide (PINP); Hemodialysis (HD)

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; OSTEOCALCIN; PYRIDINOLINE;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BONE MINERAL; CELL FUNCTION; CHRONIC KIDNEY FAILURE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PROTEIN FUNCTION;

EID: 0036788313     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.35692     Document Type: Article

References (27)

1. Garnero P, Sornay-Rendu E, Claustrat B, et al: Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 15:1526-1536, 2000
2. Peris P, Alvarez L, Monegal, et al: Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy. Bone 25:349-353, 1999
3. 3 in patients with type 2 diabetes. Osteoporos Int 9:525-531, 1999
4. Kumeda Y, Inaba M, Tahara H, et al: Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 85:4157-4161, 2000
5. Urena P, De Vernejoul MC: Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 55:2141-2156, 1999
6. Urena P, Ferreira A, Kung VT, et al: Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res 10:932-939, 1995
7. Melkko J, Hellevik T, Risteli L, Risteli J, Smedsrod B: Clearance of NH2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 179:405-412, 1994
8. Jensen PB, Rasmussen HB, Pedersen FB: Serum concentration of the aminopropeptide of type I procollagen in patients on haemo- and peritoneal dialysis. APMIS 105:371-377, 1997
9. Ishimura E, Okuno S, Kim M, et al: Increasing body fat mass in the first year of hemodialysis. J Am Soc Nephrol 12:1921-1926, 2001
10. Inaba M, Morii H, Katsumata T, et al: Hyperparathyroidism is augmented by ovariectomy in Nagase analbuminemic rats. J Nutr 130:1543-1547, 2000
11. Inaba M, Terada M, Nishizawa Y, et al: Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: Possible involvement of the polyol pathway in bone metabolism. Metabolism 48:904-909, 1999
12. Lepage R, Roy L, Brossard JH, et al: A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 44:805-809, 1998
13. Arnaud CD, Pun KK: Metabolism and assay of parathyroid hormone, in Coe FL, Favus MJ (eds): Disorders of Bone and Mineral Metabolism. New York, NY, Raven, 1992, pp 107-122
14. Tahtela R, Turpeinen M, Sorva R, Karonen S-L: The aminoterminal propeptide of type I procollagen: Evaluation of a commercial radioimmunoassay kit and values in healthy subjects. Clin Biochem 30:35-40, 1997
15. Gomes B Jr, Ardakani S, Ju J, et al: Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41:1560-1566, 1995
16. Takahashi M, Kushida K, Nagano A, Inoue T: Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay. Clin Chim Acta 294:67-76, 2000
17. Furumitsu Y, Inaba M, Yukioka K, et al: Levels of serum and synovial fluid pyridinium crosslinks in patients with rheumatoid arthritis. J Rheumatol 27:64-70, 2000
18. Niwa T, Shiobara K, Hamada T, et al: Serum pyridinolines as specific markers of bone resorption in hemodialyzed patients. Clin Chim Acta 235:33-40, 1995
19. Okabe R, Nakatsuska K, Inaba M, et al: Clinical evaluation of the Elecsys β-CrossLaps serum assay, a new assay that measures serum concentrations of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 47:1410-1414, 2001
20. Ichihara K: Statistics for Bioscience. Practical Technique and Theory. Tokyo, Japan, Nankodo, 1990, pp 233
21. Hirota Y, Kurimoto F, Hata H, Miura M: Fundamental studies on the determination of serum intact PINP (aminoterminal propeptide of type I procollagen) with RIA method [Japanese]. Horumon to Rinsyo 45:431-435, 1997
22. Inaba M, Ishikawa T, Imanishi Y, et al: Pathophysiology and diagnosis of primary hyperparathyroidism strategy for asymptomatic primary hyperparathyroidism. Biomed Pharmacother 54:S7-S11, 2000 (suppl 1)
23. Parisien M, Mellish RW, Silverberg SJ, et al: Maintenance of cancellous bone connectivity in primary hyperparathyroidism: Trabecular strut analysis. J Bone Miner Res 7:913-919, 1992
24. Wagner MS, Stracke S, Jehle PM, et al: Evaluation of IGF system component levels and mitogenic activity of uremic serum on normal human osteoblasts. Nephron 84:158-166, 2000
25. Nakayama K, Fukumoto S, Takeda S, et al: Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab 81:607-611, 1996
26. Bianda T, Glatz Y, Bouillon R, et al: Effects of short-term insulin-like growth factor-I (IGF-I) or growth hormone (GH) treatment on bone metabolism and on production of 1,25-dihydrocycholecalciferol in GH-deficient adults. J Clin Endocrinol Metab 83:81-87, 1998
27. Magnusson P, Sharp CA, Magnusson M, et al: Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney Int 60:257-265, 2001